Home›Trial›NCT07221578
NCT07221578Phase 3RECRUITING

Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

Study Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.

Conditions
Social Anxiety Disorder (SAD)
Interventions / Drugs
VQW-765Placebo
View on ClinicalTrials.gov ↗
Sponsor
VNDA
Vanda Pharmaceuticals
Neuroscience
D41/100
Study Details
Enrollment500 participants
Primary Completion—
Lead SponsorVanda Pharmaceuticals
Data Retrieved2026-04-11 04:31:05.188572+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 500 participants
Sponsor Catalyst Profile

Vanda Pharmaceuticals (VNDA) is the sponsoring company for this trial. BiotechSign currently grades this company D (41/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

VNDA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.